1-1 of 1
Jana Sanger
Close
Sort by
Journal Articles

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Nikolas von Bubnoff, Paul W. Manley, Jurgen Mestan, Jana Sanger, Christian Peschel, Justus Duyster
Journal: Blood
Blood (2006) 108 (4): 1328–1333.
https://doi.org/10.1182/blood-2005-12-010132
Published: 2006